| Literature DB >> 35270305 |
Chuan-Hsin Chang1, Yue-Cune Chang2, Luke Yang3, Ruu-Fen Tzang4,5,6.
Abstract
Internet gaming disorder (IGD) is a formal mental disorder leading to bad outcomes for children and adolescents. This study comprehensively compared the estimated effect of various pharmacotherapy and psychosocial interventions for IGD from randomized controlled trials (RCT) through updated meta-analysis, using meta-regression. A search of PubMed/MEDLINE, Cochrane Library, and Airiti Library between 2000 and 2017 was conducted for various IA/IGD intervention modalities. A total of 124 studies from 29 selected papers involving 5601 children and young adults with IA/IGD were found. Meta-analyzing the pooled standardized mean difference (SMD) revealed a preliminary random effect of 1.399 with a 95% confidence interval of 1.272-1.527, suggesting highly effective treatment of IA/IGD. After adjusting for the confounding risks of age, publication year, type of subjects, and type of study, this study revealed that combining pharmacotherapy with cognitive behavioral therapy (CBT) or multi-level counseling (MLC) was the most effective treatment option. Using a scale of time spent online or a severity of IA symptoms scale was a more effective measurement, with p-values = 0.006 and 0.002, respectively. IA/IGD patients with comorbid depression showed worse outcomes than youth with another comorbidity. The corresponding model goodness-of-fit indices were τ2 = 1.188; I2-Residual = 89.74%; and Adjusted-R2 = 16.10%. This systematic review indicates that pharmacotherapy combined with CBT or MLC might be an effective therapeutic strategy for youth with gaming disorder.Entities:
Keywords: internet addiction; internet gaming disorder; meta-regression; pharmacotherapy; psychological treatment
Mesh:
Substances:
Year: 2022 PMID: 35270305 PMCID: PMC8909504 DOI: 10.3390/ijerph19052612
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Summary of study characteristics of all included papers.
| Paper | Year | Country | No. of Studies | Age | Measurements | No. of Patients | Treatment | Type of Subjects | Treatment |
|---|---|---|---|---|---|---|---|---|---|
| Cao FL et al. | 2007 | China | 1 | 14.8 | YDQ, CIAS | 57 | 8 | IA | CBT vs. Control |
| Li G & Dai XY | 2009 | China | 1 | 16.5 | CIAS | 76 | 12 | IA | CBT vs. Control |
| Shao Z et al. | 2015 | China | 1 | 16 | SDS, SCL-90 | 66 | 8 | IA + Depression | CBT + Drug vs. CBT |
| Wei QX | 2008 | China | 1 | 17 | SAS, SDS | 60 | 12 | IA | Others (Psychology Nursing) |
| Yang FR et al. | 2005 | China | 1 | 15.2 | IAD-DQ, SCL-90, Time | 52 | 12 | IA | SFBT (No control) |
| Liao XC | 2010 | China | 1 | 15 | IAD-DQ, SCL-90 | 284 | 32 | IA + Depression | CBT + Drug vs. CBT |
| Wu LZ et al. | 2007 | China | 1 | 19.5 | Time | 27 | 6 | IA | Others (HANS) vs. Control |
| Pan SJ et al. | 2010 | China | 1 | 17 | CIAS, SCL-90, SDS | 11 | 16 | IA | Others (EEG Biofeedback) |
| Liao YR et al. | 2012 | Taiwan | 1 | 14 | CIAS-R, Time | 18 | 8 | IA | Others (Adlerian Group Counseling) |
| Li & Dai | 2009 | China | 1 | 16.5 | CIAS | 76 | 9 | IA | CBT vs. Control |
| Bai & Fan | 2007 | China | 1 | 19 | CIAS | 48 | 8 | IA | MLC vs. Control |
| Du YS et al. | 2010 | China | 1 | 15.9 | IOSRS | 56 | 8 | IA | CBT vs. Control |
| Han DH et al. | 2009 | Korea | 1 | 9.3 | YIAS-K, Time | 62 | 8 | IA + ADHD | Drug (Methylphenidate) (No control) |
| Yang R et al. | 2005 | China | 1 | 16 | CIUS, SDS, SCL-90 | 18 | 8 | IA | MLC + Drug (Fluoxetine) + Others |
| Zhu TM et al. | 2009 | China | 1 | 22.2 | ISS, SAS, SDS, HAMA, HAMD | 45 | 20, 10 | IA | CBT+ acupuncture vs. CBT |
| Yeun YR et al. | 2016 | Korea | 33 | 8~12 | K-scale, YIAS, IGAS | 1330 | 6~22 | IA | CBT, MLC, CBT/MLC + Others, |
| Liu J et al. | 2017 | China, Korea | 49 | 15.5~20 | IA | 2304 | IA | CBT, MLC, Others | |
| Winkler et al. | 2013 | China, Korea, US | 16 | 14.8~23 | Anx., Dep., IA, Time | 454 | IA | Drug, CBT, MLC, Others | |
| Liu QX et al. | 2015 | China | 1 | 15.7 | APIUS, Time | 46 | 6 | IA | MLC vs. Control |
| Yang Y et al. | 2017 | China | 1 | 21.1, 21.7 | YIAS | 32 | 10, 20 | IA | CBT vs. Electro-acupuncture |
| Han DH et al. | 2012 | Korea | 1 | 20.2 | YIAS, BDI, Time | 50 | 8 | IA + Depression | Drug (Bupropion) |
| Park JH et al. | 2016 | Korea | 1 | 17 | YIAS, CDI | 86 | 12 | IA + ADHD | Drug (Methylphenidate) vs. |
| Mun SY et al. | 2015 | Korea | 1 | 10.5 | IA, Time | 56 | 8 | IA | CBT vs. Control |
| Lien T.-C. | 2007 | Taiwan | 1 | 16.8 | YDQ | 20 | 8 | IA | MLC vs. Control |
| Huang Z et al. | 2010 | China | 1 | 21 | CGAI | 27 | 6 | IA | MLC vs. Control |
| Khazaei et al. | 2017 | Iran | 1 | 20 | YIAS | 48 | 10 | IA | CBT (Positive psychology |
| Hui Li et al. | 2017 | China | 1 | 22 | ISS, SCL-90 | 112 | 10 | IA | CBT + Others (EA) vs. |
| Kim SM et al. | 2012 | Korea | 1 | 16 | YIAS, BAI, BDI, Time | 65 | 8 | IA + Depression | CBT + Drug (Bupropion) |
| Han DH et al. | 2012 | Korea | 1 | 14.2 | YIAS, Time | 15 | 12 | IA | MLC (No control) |
RP: Routine Pharmacotherapy.
Results of univariate meta-regression analysis.
| SMD | Coefficients | SE | t |
| τ2 | I2-Residual | Adjusted-R2 | No. |
|---|---|---|---|---|---|---|---|---|
| Year | 0.025 | 0.027 | 0.93 | 0.354 | 1.415 | 93.00% | 0.05% | 207 |
| Mean Age | 0.062 | 0.025 | 2.51 | 0.013 | 1.36 | 92.52% | 3.99% | 207 |
| Treatments | 1.39 | 93.00% | 1.83% | 207 | ||||
| Treat 2 vs. Treat 1 | 0.613 | 0.320 | 1.92 | 0.056 | ||||
| Treat 3 vs. Treat 1 | 0.263 | 0.311 | 0.85 | 0.398 | ||||
| Treat 4 vs. Treat 1 | 0.834 | 0.427 | 1.96 | 0.052 | ||||
| Treat 5 vs. Treat 1 | 0.665 | 0.408 | 1.63 | 0.104 | ||||
| Treat 6 vs. Treat 1 | 0.269 | 0.377 | 0.71 | 0.477 | ||||
| Measurements | 1.39 | 91.89% | 1.80% | 207 | ||||
| Type 2 vs. Type 1 | 0.137 | 0.384 | 0.36 | 0.722 | ||||
| Type 3 vs. Type 1 | 0.533 | 0.309 | 1.73 | 0.086 | ||||
| Type 4 vs. Type 1 | 0.744 | 0.406 | 1.83 | 0.068 | ||||
| Type 5 vs. Type 1 | −0.107 | 0.531 | −0.20 | 0.841 | ||||
| Study Types | 1.432 | 92.87% | −1.13% | 207 | ||||
| StudType 2 vs StudType 1 | −0.077 | 0.265 | −0.29 | 0.772 | ||||
| StudType 3 vs StudType 1 | −0.298 | 0.310 | −0.96 | 0.338 | ||||
| StudType 4 vs StudType 1 | −0.211 | 0.267 | −0.79 | 0.429 | ||||
| Types of Subjects | 1.402 | 92.66% | 1.01% | 207 | ||||
| PType 2 vs. PType 1 | −0.487 | 0.356 | −1.37 | 0.172 | ||||
| PType 3 vs. PType 1 | −0.726 | 0.526 | −1.38 | 0.169 | ||||
| Group Therapy | 1.420 | 93.01% | −0.29% | 207 | ||||
| Yes vs. No | −0.126 | 0.188 | −0.67 | 0.503 | ||||
| Parents Involved in the Therapy program | 1.441 | 93.07% | −0.02% | 203 | ||||
| Yes vs. No | 0.188 | 0.221 | 0.85 | 0.396 | ||||
Treatments: Treat 1: Drugs; Treat 2: CBT (Cognitive Behavioral Therapy); Treat 3: MLC (Multi-level Counseling Program); Treat 4: Drug + CBT or MLC; Treat 5: Others + CBT or MLC; Treat 6: Others; Measurements: Type 1: Anxiety; Type 2: Depression; Type 3: Internet Addiction Scale; Type 4: Online Time Spent (Hours of Internet Use); Type 5: Others; Study Types: StudType 1: Two groups with pre- and post-tests; StudType 2: One group with pre-test and post-test; StudType 3: Two groups post-test only; StudType 4: Using Hedge’s g and se(G) directly; Types of Subjects: PType 1: IA; PType 2: IA + Depression; PType 3: IA + ADHD.
Results of multiple meta-regression analysis (Using significant terms only).
| SMD | Coefficients | SE | t |
| τ2 | I2-Residual | Adjusted-R2 | No. |
|---|---|---|---|---|---|---|---|---|
| 1.209 | 90.32% | 14.65% | 207 | |||||
| Mean Age | 0.087 | 0.025 | 3.53 | 0.001 | ||||
| Treatments | ||||||||
| Treat 2 vs. Treat 1 | 0.623 | 0.315 | 1.98 | 0.049 | ||||
| Treat 3 vs. Treat 1 | 0.152 | 0.309 | 0.49 | 0.624 | ||||
| Treat 4 vs. Treat 1 | 1.175 | 0.409 | 2.87 | 0.005 | ||||
| Treat 5 vs. Treat 1 | 0.829 | 0.399 | 2.08 | 0.039 | ||||
| Treat 6 vs. Treat 1 | 0.382 | 0.370 | 1.03 | 0.302 | ||||
| Measurements | ||||||||
| Type 2 vs. Type 1 | 0.232 | 0.369 | 0.63 | 0.531 | ||||
| Type 3 vs. Type 1 | 0.880 | 0.304 | 2.89 | 0.004 | ||||
| Type 4 vs. Type 1 | 1.171 | 0.398 | 2.94 | 0.004 | ||||
| Type 5 vs. Type 1 | −0.089 | 0.504 | −0.18 | 0.860 |
τ2: The estimate of between-study variance; I2-Residual: Residual variation due to heterogeneity in percentage; Adjusted-R2: Proportion of between-study variance explained by the current model. Treatments: Treat 1: Drugs; Treat 2: CBT (Cognitive Behavioral Therapy); Treat 3: MLC (Multi-level Counseling Program); Treat 4: Drug + CBT or MLC; Treat 5: Others + CBT or MLC; Treat 6: Others; Measurements: Type 1: Anxiety; Type 2: Depression; Type 3: Internet Addiction Scale; Type 4: Online Time Spent (Hours of Internet Use); Type 5: Others.
Figure 1Meta-regression plot, τ2 = 1.209, I2-Residual = 90.32%, Adjusted-R2 = 14.65%, n = 207.
Figure 2Meta-regression plot, τ2 = 1.188, I2-Residual = 89.74%, Adjusted-R2 = 16.10%, n = 207.
Results of multiple meta-regression analysis (with all collected potential confounding variables).
| SMD | Coefficients | SE | t |
| τ2 | I2-Residual | Adjusted-R2 | No. |
|---|---|---|---|---|---|---|---|---|
| 1.188 | 89.74% | 16.10% | 207 | |||||
| Mean Age | 0.125 | 0.037 | 3.33 | 0.001 | ||||
| Treatments | ||||||||
| Treat 2 vs. Treat 1 | 0.528 | 0.365 | 1.45 | 0.150 | ||||
| Treat 3 vs. Treat 1 | 0.092 | 0.374 | 0.25 | 0.805 | ||||
| Treat 4 vs. Treat 1 | 1.044 | 0.458 | 2.28 | 0.024 | ||||
| Treat 5 vs. Treat 1 | 0.505 | 0.462 | 1.09 | 0.276 | ||||
| Treat 6 vs. Treat 1 | 0.171 | 0.422 | 0.41 | 0.685 | ||||
| Measurements | ||||||||
| Type 2 vs. Type 1 | 0.283 | 0.370 | 0.76 | 0.446 | ||||
| Type 3 vs. Type 1 | 1.027 | 0.321 | 3.20 | 0.002 | ||||
| Type 4 vs. Type 1 | 1.125 | 0.409 | 2.75 | 0.006 | ||||
| Type 5 vs. Type 1 | −0.318 | 0.514 | −0.62 | 0.536 | ||||
| Year | −0.007 | 0.030 | −0.22 | 0.823 | ||||
| PType 2 vs. PType 1 | −0.681 | 0.383 | −1.78 | 0.077 | ||||
| PType 3 vs. PType 1 | −0.323 | 0.624 | −0.52 | 0.605 | ||||
| StudType 2 vs. StudType 1 | 0.115 | 0.301 | 0.38 | 0.702 | ||||
| StudType 3 vs. StudType 1 | 0.131 | 0.420 | 0.31 | 0.757 | ||||
| StudType 4 vs. StudType 1 | −0.553 | 0.280 | −1.97 | 0.050 |
Treatments: Treat 1: Drugs; Treat 2: CBT (Cognitive Behavioral Therapy); Treat 3: MLC (Multi-level Counseling Program); Treat 4: Drug +CBT or MLC; Treat 5: Others + CBT or MLC; Treat 6: Others; Measurements: Type 1: Anxiety; Type 2: Depression; Type 3: Internet Addiction Scale; Type 4: Online Time Spent (Hours of Internet Use); Type 5: Others; Study Types: StudType 1: Two groups with pre- and post-tests; StudType 2: One group with pre-test and post-test; StudType 3: Two groups post-test only; StudType 4: Using Hedge’s g and se(G) directly; Types of Subjects: PType 1: IA; PType 2: IA + Depression; PType 3: IA + ADHD.
Figure 3Funnel plots for treatment effects of children and adolescents with Internet addiction. The Egger’s regression intercept testing for bias was significant.